ABT Looks 22.9% Undervalued on GF Value™ with Strong Dividend Sustainability

gurufocus.com · 2026-09-14

On September 14, 2026, Abbott Laboratories (NYSE: ABT) announced a $385 million settlement with the U.S. Department of Justice related to its 2022 baby formula

TickrTrends take: ABT's current undervalued designation aligns with the GF Value assessment, suggesting the stock may offer value relative to its fundamentals in the Healthcare sector. Investors focused on valuation metrics should monitor whether the company's dividend sustainability metrics remain robust, as dividend reliability is often a key factor that distinguishes truly undervalued opportunities from value traps. The convergence of TickrTrends' undervalued verdict with the external GF Value assessment provides multiple analytical perspectives on the stock's current positioning.

Read the full story at gurufocus.com →